Public Funding for Avacta Life Sciences Limited

To validate multiplexed tests using Affimer technology for early detection of bacterial infections and sepsis

Promexus is a new biotechnology company which will be developing a novel human therapeutic protein (the Affimer) that will address some of the shortcomings of the current antibody based drugs. Antibodies have been very successful at treating a wide range of human disease such as asthma, arthritis and cancer, but they are expensive to produce and because of their large size can only be given via an injection. Affimers should be cheaper to make and because they are smaller and stable, can be administered topically (for example to the skin as a cream or to the lungs using an inhaler). Our first drug will be for the treatment of cancer where there is a need for cheaper more effective drugs. Affimers have all the properties to potentially make the next generation of therapeutics to meet the demand of new medicines